- Home
- MPB vs MLYS Comparison
MPB vs MLYS Comparison
Compare MPB & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MPB | MLYS |
|---|---|---|
| Founded | 1868 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 738.9M | 3.1B |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | MPB | MLYS |
|---|---|---|
| Price | $31.73 | $37.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $37.00 | ★ $47.33 |
| AVG Volume (30 Days) | 92.9K | ★ 1.6M |
| Earning Date | 01-21-2026 | 02-11-2026 |
| Dividend Yield | ★ 2.74% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.40 | N/A |
| Revenue | ★ $208,869,000.00 | N/A |
| Revenue This Year | $26.19 | N/A |
| Revenue Next Year | $28.25 | N/A |
| P/E Ratio | $13.21 | ★ N/A |
| Revenue Growth | ★ 20.73 | N/A |
| 52 Week Low | $22.50 | $8.24 |
| 52 Week High | $33.24 | $47.65 |
Technical Indicators
Market Signals| Indicator | MPB | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 59.99 | 44.26 |
| Support Level | $31.64 | $36.01 |
| Resistance Level | $33.24 | $38.23 |
| Average True Range (ATR) | 0.63 | 1.77 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 56.77 | 42.59 |
Price Performance
Historical ComparisonAbout MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.